Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2012 09:15 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika Pharma Announces Close of First Tranche of Private Placement of Units

EDMONTON, Alberta, Oct. 18, 2012 (GLOBE NEWSWIRE) -- Further to its press release of October 16, 2012, Isotechnika Pharma Inc. (TSX:ISA) announced today that it has completed the first tranche of its...
October 16, 2012 16:38 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika Pharma Announces Private Placement of Units

EDMONTON, Alberta, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) intends to complete a non-brokered private placement of up to 21.25 million units of Isotechnika at a price of 4...
August 14, 2012 18:35 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika Reports Second Quarter 2012 Financial Results

EDMONTON, Alberta, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) today announced financial results for the second quarter ended June 30, 2012. The Company's financial and...
July 17, 2012 08:00 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika Pharma Receives Additional Funding From the Government of Canada for NICAM Program

EDMONTON, Alberta, July 17, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") today announced that it has received approval for funding from the National...
July 09, 2012 08:11 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika Pharma's Partner Lux Biosciences Completes Enrollment in Phase 3 Uveitis Study

EDMONTON, Alberta, July 9, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika") announced today that Lux Biosciences, Inc. ("Lux") has completed patient enrollment in its Phase 3...
July 05, 2012 08:30 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika to Present at JMP Securities Healthcare Conference

EDMONTON, Alberta, July 5, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that its CEO, Dr. Robert Foster, will present an update on the...
June 28, 2012 08:50 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika Pharma's Partner 3SBio Recieves Approval for Phase 3 Trial of Voclosporin in China

EDMONTON, Alberta, June 28, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that 3SBio Inc. (Nasdaq:SSRX), a leading China-based...
May 11, 2012 17:00 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika Reports First Quarter 2012 Financial Results

EDMONTON, Alberta, May 11, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) today announced financial results for the three months ended March 31, 2012. Financial Results For the first...
April 11, 2012 10:35 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika Pharma Announces Agreement With U.S. National Institutes of Health to Evaluate NICAM Portfolio as Anti-Viral Agents

EDMONTON, Alberta, April 11, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") is pleased to announce the signing of a three year Non-Clinical Evaluation...
March 28, 2012 08:00 ET | Source: Aurinia Pharmaceuticals Inc.

Isotechnika Recieves Notice of ILJIN's Request for Arbitration

EDMONTON, Alberta, March 28, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") announced today that, further to its press release of January 31, 2012, it has...